Eisai Starts Marketing Severe Chronic Pain Agent Prialt in the UK and Germany
Eisai Ltd. (Managing Director: Paul Hooper) of the UK and Eisai GmbH (General Manager: Andreas Wiegand) of Germany, subsidiaries of Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) started marketing non-opioid severe chronic pain agent Prialt (generic name: ziconotide acetate) in the UK and Gemany respectively. Other subsidiaries in Europe will follow.
Eisai concluded an agreement with Elan Corporation, plc. of Ireland, (President and CEO: Kelly Martin) for the strategic product acquisition of Prialt on February 8th, 2006 to obtain development, manufacturing and marketing rights for Prialt for the European region from Elan.
Prialt is a peptide which is the synthetic equivalent of a peptide found in a marine snail. It suppresses pain by selectively blocking N-type calcium channels on nerves. In December 2004, the US FDA approved Prialt for the management of severe, chronic pain in patients who require intrathecal analgesia. Prialt has been awarded an orphan drug status in the European Union, and was granted a Marketing Authorization through the European Union's Centralized Procedure in February 2005. Prialt is the first medicine that was approved in Europe as a non-opioid, intrathecal, severe chronic pain agent.
Prialt's launch in Europe means that Eisai steps into oncology and critical care which is one of our franchise areas and believes that Prialt will meet the needs of patients with severe chronic pain in Europe and contribute to increase their benefits.
Corporate Communications Department
Eisai Co., Ltd.
[See the attached for the outline of Prialt as a reference]
< Note to editors >